Clinical Trials Browser

Phase 1/2 × Metastatic HER2 Positive Gastroesophageal Junction Cancer × Trastuzumab × Clear all

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer